The 2022 EULAR/ACR Points to Consider at the Early Stages of Diagnosis and Management of Suspected Haemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome (HLH/MAS)
© 2023 American College of Rheumatology..
OBJECTIVE: Haemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS) are life-threatening systemic hyperinflammatory syndromes that can develop in most inflammatory contexts. They can progress rapidly, and early identification and management are critical for preventing organ failure and mortality. This effort aimed to develop evidence-based and consensus-based points to consider to assist clinicians in optimising decision-making in the early stages of diagnosis, treatment and monitoring of HLH/MAS.
METHODS: A multinational, multidisciplinary task force of physician experts, including adult and paediatric rheumatologists, haematologist/oncologists, immunologists, infectious disease specialists, intensivists, allied healthcare professionals and patients/parents, formulated relevant research questions and conducted a systematic literature review (SLR). Delphi methodology, informed by SLR results and questionnaires of experts, was used to generate statements aimed at assisting early decision-making and optimising the initial care of patients with HLH/MAS.
RESULTS: The task force developed 6 overarching statements and 24 specific points to consider relevant to early recognition of HLH/MAS, diagnostic approaches, initial management and monitoring of HLH/MAS. Major themes included the simultaneous need for prompt syndrome recognition, systematic evaluation of underlying contributors, early intervention targeting both hyperinflammation and likely contributors, careful monitoring for progression/complications and expert multidisciplinary assistance.
CONCLUSION: These 2022 EULAR/American College of Rheumatology points to consider provide up-to-date guidance, based on the best available published data and expert opinion. They are meant to help guide the initial evaluation, management and monitoring of patients with HLH/MAS in order to halt disease progression and prevent life-threatening immunopathology.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:75 |
|---|---|
| Enthalten in: |
Arthritis & rheumatology (Hoboken, N.J.) - 75(2023), 10 vom: 02. Okt., Seite 1714-1732 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Shakoory, Bita [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Journal Article |
|---|
| Anmerkungen: |
Date Completed 23.10.2023 Date Revised 26.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/art.42636 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM359869548 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM359869548 | ||
| 003 | DE-627 | ||
| 005 | 20240426233238.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/art.42636 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1388.xml |
| 035 | |a (DE-627)NLM359869548 | ||
| 035 | |a (NLM)37486733 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Shakoory, Bita |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The 2022 EULAR/ACR Points to Consider at the Early Stages of Diagnosis and Management of Suspected Haemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome (HLH/MAS) |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.10.2023 | ||
| 500 | |a Date Revised 26.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 American College of Rheumatology. | ||
| 520 | |a OBJECTIVE: Haemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS) are life-threatening systemic hyperinflammatory syndromes that can develop in most inflammatory contexts. They can progress rapidly, and early identification and management are critical for preventing organ failure and mortality. This effort aimed to develop evidence-based and consensus-based points to consider to assist clinicians in optimising decision-making in the early stages of diagnosis, treatment and monitoring of HLH/MAS | ||
| 520 | |a METHODS: A multinational, multidisciplinary task force of physician experts, including adult and paediatric rheumatologists, haematologist/oncologists, immunologists, infectious disease specialists, intensivists, allied healthcare professionals and patients/parents, formulated relevant research questions and conducted a systematic literature review (SLR). Delphi methodology, informed by SLR results and questionnaires of experts, was used to generate statements aimed at assisting early decision-making and optimising the initial care of patients with HLH/MAS | ||
| 520 | |a RESULTS: The task force developed 6 overarching statements and 24 specific points to consider relevant to early recognition of HLH/MAS, diagnostic approaches, initial management and monitoring of HLH/MAS. Major themes included the simultaneous need for prompt syndrome recognition, systematic evaluation of underlying contributors, early intervention targeting both hyperinflammation and likely contributors, careful monitoring for progression/complications and expert multidisciplinary assistance | ||
| 520 | |a CONCLUSION: These 2022 EULAR/American College of Rheumatology points to consider provide up-to-date guidance, based on the best available published data and expert opinion. They are meant to help guide the initial evaluation, management and monitoring of patients with HLH/MAS in order to halt disease progression and prevent life-threatening immunopathology | ||
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Intramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 700 | 1 | |a Geerlinks, Ashley |e verfasserin |4 aut | |
| 700 | 1 | |a Wilejto, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a Kernan, Kate |e verfasserin |4 aut | |
| 700 | 1 | |a Hines, Melissa |e verfasserin |4 aut | |
| 700 | 1 | |a Romano, Micol |e verfasserin |4 aut | |
| 700 | 1 | |a Piskin, David |e verfasserin |4 aut | |
| 700 | 1 | |a Ravelli, Angelo |e verfasserin |4 aut | |
| 700 | 1 | |a Sinha, Rashmi |e verfasserin |4 aut | |
| 700 | 1 | |a Aletaha, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Allen, Carl |e verfasserin |4 aut | |
| 700 | 1 | |a Bassiri, Hamid |e verfasserin |4 aut | |
| 700 | 1 | |a Behrens, Edward M |e verfasserin |4 aut | |
| 700 | 1 | |a Carcillo, Joseph |e verfasserin |4 aut | |
| 700 | 1 | |a Carl, Linda |e verfasserin |4 aut | |
| 700 | 1 | |a Chatham, Winn |e verfasserin |4 aut | |
| 700 | 1 | |a Cohen, Jeffrey I |e verfasserin |4 aut | |
| 700 | 1 | |a Cron, Randy Q |e verfasserin |4 aut | |
| 700 | 1 | |a Drewniak, Erik |e verfasserin |4 aut | |
| 700 | 1 | |a Grom, Alexei A |e verfasserin |4 aut | |
| 700 | 1 | |a Henderson, Lauren A |e verfasserin |4 aut | |
| 700 | 1 | |a Horne, Annacarin |e verfasserin |4 aut | |
| 700 | 1 | |a Jordan, Michael B |e verfasserin |4 aut | |
| 700 | 1 | |a Nichols, Kim E |e verfasserin |4 aut | |
| 700 | 1 | |a Schulert, Grant |e verfasserin |4 aut | |
| 700 | 1 | |a Vastert, Sebastiaan |e verfasserin |4 aut | |
| 700 | 1 | |a Demirkaya, Erkan |e verfasserin |4 aut | |
| 700 | 1 | |a Goldbach-Mansky, Raphaela |e verfasserin |4 aut | |
| 700 | 1 | |a de Benedetti, Fabrizio |e verfasserin |4 aut | |
| 700 | 1 | |a Marsh, Rebecca A |e verfasserin |4 aut | |
| 700 | 1 | |a Canna, Scott W |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Arthritis & rheumatology (Hoboken, N.J.) |d 2014 |g 75(2023), 10 vom: 02. Okt., Seite 1714-1732 |w (DE-627)NLM234543671 |x 2326-5205 |7 nnns |
| 773 | 1 | 8 | |g volume:75 |g year:2023 |g number:10 |g day:02 |g month:10 |g pages:1714-1732 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/art.42636 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 75 |j 2023 |e 10 |b 02 |c 10 |h 1714-1732 | ||